linjc16/ctgov huggingface dataset:
Influence of Consecutive Strength- and Endurance Regimes on the Myonuclear Domain and Satellite Cell in the M. Vastus Lateralis of Old Healthy Men

Study Overview
=================
Brief Summary
-----------------
Randomised training intervention. Influence of consecutive training regime on the impact of the myonuclear domain and satellite cell Sarcopenia Despite that the muscle mass can be positively influenced by training, the loading with high weights and/or to the total exhaustion is for many old persons not possible. Therefore we aim to enhance the myonuclei in the muscle fiber of old male subjects in a first phase by endurance training, in order to promote a more effective muscle growth in a second phase by resistance exercise.

Conditions
-----------------
Regeneration Potential of Healthy Old Men in Terms of Satellite Cell Activation

Intervention / Treatment
-----------------
* Procedure: Training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: -male no fever at the beginning and during the study between 60 years and 75 years non smokers no known cardiovascular and orthopaedic problems no cardiac pacemaker fulfilling the health criteria Exclusion criteria: -female fever or cold at the beginning or during the study non MRI compatible metal implants under 60 years or over 75 years smoker cardiovascular or orthopaedic problems cardiac pacemaker not fulfilling the health criteria

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Endurance and Resistance Training<br>Endurance and resistance exercise | Procedure: Training<br> <br> |
| Experimental: Resistance Training<br>resistance exercise (12wk) | Procedure: Training<br> <br> |
| Experimental: Resistance and resistance Training<br>resistance exercise (24 wk) | Procedure: Training<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference in % from baseline in fibre type specific number of satellite cells, fibre type specific myonuclear domain [um^2], myonuclear number [%] in response to consecutive training regimes | Difference in % from baseline in fibre type specific number of satellite cells, fibre type specific myonuclear domain [um^2], myonuclear number [%] in response to consecutive training regimes | participants will be followed for the duration of training period, an expected average of 7 months |
Impact of COVID-19 on Pediatric Dental Practice During First, Second And Third Wave.

Study Overview
=================
Brief Summary
-----------------
Assessment of impact of covid-19 on pediatric dental practice during first, second and third wave among a group of pediatric dentists.

Detailed Description
-----------------
On the 11th of March, 2020, COVID-19 (SARS-CoV-2) was declared as a pandemic by the World Health Organization. SARS-CoV-2 is an unpredictable virus that is rapidly transmitting from one country to another, and unfortunately as of today, there is no effective medication or vaccine for the disease control. This virus has gone on to cause one of the most rapidly expanding pandemics with over 9 million people being infected worldwide including the pediatric population. Due to the unique nature of dentistry, most dental procedures generate significant amounts of droplets and aerosols, posing potential risks of infection transmission. Recent studies have demonstrated the role of the oral mucosa in COVID-19 infection, in addition to expressing the ACE2 receptor in salivary glands in the asymptomatic process in infected saliva, thus being one of the main sources of viruses. Clinical features of COVID-19 in children include fever and cough, but a large proportion of infected children appears to be asymptomatic and may contribute significantly to transmission. Therefore, it can be assumed that, at this stage in the pandemic, all children and their parents/carers are potentially infective with the potential of cross-infection to dental stuff, parents and the public. This has, in theory, an impact on medical and dental procedures that are Aerosol Generating Procedures.

Official Title
-----------------
Impact of COVID-19 on Pediatric Dental Practice During First, Second And Third Wave Among a Group of Pediatric Dentists : A Cross -Sectional Study

Conditions
-----------------
SARS-CoV2

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Egyptian pediatric dentists with at least Master's degree. Work place located in Egypt. Exclusion Criteria: Participants who refuse to participate.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Attitude of pediatric dentists toward treating patients in time of COVID-19. | Measuring device by Questionnaire (Ahmadi, Ebrahimi & Ghorbani, 2020) and (Sinjari et al., 2020). The primary outcome is measured using 5-point likert scale scoring to evaluate pediatric dentists' attitudes | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COVID-19, pediatric dentistry
Changes in Breast 3D Ultrasound Measurements Using Toremifene

Study Overview
=================
Brief Summary
-----------------
To investigate if there are detectable changes in volume and circulation in breasts of healthy volunteers using toremifene 20 mg in luteal phase of the menstruation cycle versus nonmedicated cycle.

Detailed Description
-----------------
20 women were participated to this trial.

Official Title
-----------------
Volume and Circulation Changes of The Breast in 3D Ultrasound During Toremifene Versus Nonmedicated Menstrual Cycle

Conditions
-----------------
Circulatory; Change

Intervention / Treatment
-----------------
* Drug: Toremifene


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 25-45 healthy person regular menstrual cycles safe contraception(for example sterilization or condom) Exclusion Criteria: gynecological or other type of cancer hormonal contraception pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Toremifene<br> | Drug: Toremifene<br>* 20mg toremifene per day in tablet form starting from the cycle day 15 and continued to premenstrual period. Medication using about 10 days per volunteer<br>* Other names: trade name Fareston;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| circulation changes of the breast |  | cycle day 23 to 26 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
toremifene
High Sensitive Troponin T (hsTnT) and Copeptin as Prognostic Parameters in Patients With Elective Total Endoprosthesis

Study Overview
=================
Brief Summary
-----------------
Summary: The purpose of the study is to prove if the biomarker high sensitive troponin T (hsTnT) and the biomarker of endogenous stress copeptin can serve as surrogate parameter of prognosis in patients with elective knee and hip total endoprosthesis.

Detailed Description
-----------------
Consecutively, high sensitive troponin T and copeptin will be measured in all patients with elective knee and hip endoprosthesis in the orthopedic department of the University of Heidelberg. The blood is taken during the routine blood testes if possible, on admission and the days 1-4 following the operation. Usual baseline characteristics are taken as well as usual blood results (hb, cholesterol and so on). Primary endpoint is the detection of perioperative myocardial infarction and pulmonary embolism.

Official Title
-----------------
High Sensitive Troponin T (hsTnT) and Copeptin as Prognostic Parameters in Patients With Elective Knee and Hip Endoprosthesis

Conditions
-----------------
Perioperative Myocardial Infarctions, Pulmonary Embolism

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Consecutive patients with elective knee and hip endoprosthesis Exclusion Criteria: Not willing or not able to take part in the observational trial No written inform consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| elective knee and limb endoprothesis<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of perioperative myocardial infarction and pulmonary embolism |  | Until 96h after operation |
Safety and Effectiveness of an Anti-HIV Drug Combination Taken Twice Daily

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to see whether taking indinavir (IDV) plus ritonavir (RTV) plus stavudine (d4T) plus lamivudine (3TC) 2 times each day is safe and can lower the level of HIV in the blood.

Detailed Description
-----------------
Patients take IDV plus RTV plus d4T plus 3TC twice daily for 24 weeks. Every 4 weeks, patients have physical exams and laboratory tests of blood and urine, and CD4 cell counts and plasma viral RNA are measured. At Week 24, the proportion of patients with plasma viral RNA below 400 copies/ml is determined to identify any clinically meaningful antiretroviral activity for the drug regimen. An observed response proportion of 80% or higher will be considered clinically meaningful.

Official Title
-----------------
A Multicenter, Open-Label, 24-Week Pilot Study to Evaluate the Safety and Efficacy of Indinavir Sulfate 800 Mg b.i.d. in Combination With Ritonavir 100 Mg/d4T/3TC b.i.d. in HIV-Infected Individuals

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Drug: Indinavir sulfate
* Drug: Ritonavir
* Drug: Lamivudine
* Drug: Stavudine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Patients may be eligible for this study if they: Are HIV-positive. Have a CD4 cell count of 75 cells/mm3 or more and a viral load of 5,000 copies/ml or more. Are age 16 or older (consent of a parent or guardian required if under 18). Agree to practice abstinence or use barrier methods of birth control (such as condoms). Are willing to stop taking all anti-HIV drugs except study drugs. (Patients may be able to continue taking drugs for other infections.) Exclusion Criteria Patients will not be eligible for this study if they: Have cancer, lung disease, severe hepatitis, or active AIDS-related infections. (Certain AIDS-related infections such as Kaposi's sarcoma may be allowed). Have ever taken 3TC, abacavir (ABC), or a protease inhibitor (such as IDV or RTV). Have changed their medications in the last 2 weeks. Are allergic to IDV, RTV, d4T, or 3TC. Have used certain medications (see the technical summary for more detail). Are pregnant or breast-feeding.

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Indinavir sulfate|nan|
|Drug: Ritonavir|nan|
|Drug: Lamivudine|nan|
|Drug: Stavudine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Drug Therapy, Combination, Stavudine, HIV Protease Inhibitors, Ritonavir, Lamivudine, Indinavir, Reverse Transcriptase Inhibitors, Anti-HIV Agents, Viral Load
Enteral Glutamine Supplementation for the Patient With Major Torso Trauma

Study Overview
=================
Brief Summary
-----------------
Glutamine is considered a conditionally essential amino acid during critical illness. After severe trauma, glutamine supplementation into the gastrointestinal tract may help maintain bowel function. We hypothesize that for the major torso trauma patient, high dose glutamine given enterally during resuscitation from shock and continued during enteral nutrition support is absorbed, available systemically and preserves gut integrity.

Detailed Description
-----------------
In this prospective, randomized, controlled trial of patients with major torso trauma, high-dose enteral glutamine and enteral nutrition will be given to research subjects while controls will receive isocaloric, isonitrogenous enteral support. Enteral tolerance, bowel integrity and permeability will be evaluated. The systemic appearance of glutamine will be measured.

Official Title
-----------------
Early Enteral Glutamine Supplement to Enteral Nutrition Support of the Major Torso Trauma Patient: Proposal for a Prospective Randomized Clinical Trial

Conditions
-----------------
Shock, Trauma, Critical Illness

Intervention / Treatment
-----------------
* Drug: Glutamine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult trauma patients meeting criteria for shock resuscitation Major torso trauma Admission to the Shock/Trauma Intensive Care Unit Exclusion Criteria: Age <18 years Pregnant Expected survival < 24 hours Bowel in discontinuity Renal failure: baseline serum creatinine>3.0 and/or dialysis Admission total bilirubin >10 mg/dl History of cirrhosis or cirrhosis apparent on exploratory laparotomy Asystole or CPR required

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Glutamine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gut function |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Systemic appearance of glutamine |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Trauma, Critical Illness, Shock, Enteral Nutrition, Glutamine
Expectations About the COVID-19 Vaccines

Study Overview
=================
Brief Summary
-----------------
This study collects information on expectations and attitudes towards the COVID-19 vaccines in participants about to receive a COVID-19 vaccine. This information will be linked to data on side effect occurrence collected in an independent study.

Detailed Description
-----------------
General hypothesis: Negative expectations and attitudes towards the vaccine are associated with a higher risk of side effects

Official Title
-----------------
Expectations About the COVID-19 Vaccines

Conditions
-----------------
Vaccine Adverse Reaction

Intervention / Treatment
-----------------
* Biological: COVID-19 vaccine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must have signed up to receive a COVID-19 vaccine in Denmark Participants are also a part of the ENFORCE study from which outcome data is obtained Must be able to read and understand Danish

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Adults receiving COVID-19 vaccine<br>Adults about to receive a COVID-19 vaccine fill out a questionnaire of potential predictors of side effect occurrence | Biological: COVID-19 vaccine<br>* Adults about to receive a COVID-19 vaccine fill out a questionnaire of potential predictors of side effect occurrence<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of local and systemic reactions (self-report) | Data obtained from independent study | 7 days after vaccination | 
| Rate of local and systemic reactions (self-report) | Data obtained from independent study | 14 days after vaccination | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Grade 1-4 and serious adverse events | Data obtained from independent study | 3-6 months after vaccination |
Assessing the Preparedness and Knowledge of Pharmacists in the Current Monkeypox Outbreak

Study Overview
=================
Brief Summary
-----------------
General objective: to measure the preparedness of pharmacists and medical interns about monkeypox Specific objectives: to evaluate the level of knowledge among pharmacists and medical interns about monkeypox treatment and nature of disease

Detailed Description
-----------------
Globally, the ongoing outbreak was declared as a public health emergency. After the first laboratory-confirmed case of monkeypox was reported in Singapore on May 2019, countries all over the world started to strengthen disease surveillance systems. One challenge in preventing monkeypox is a lack of knowledge, particularly among healthcare workers. Study significance: to examine in detail the preparedness and the perception of pharmacists and medical interns about monkeypox and to evaluate the level of knowledge about monkeypox management and nature of disease.

Official Title
-----------------
Comparative Study of the Preparedness and Knowledge of Pharmacists Versus Intern Physician in the Current Monkeypox Outbreak

Conditions
-----------------
Monkey Pox

Intervention / Treatment
-----------------
* Other: Questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - community, hospital and clinical pharmacists, Medical interns of both sexes Exclusion Criteria: any other healthcare professional
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pharmacists<br>community, hospital and clinical pharmacists | Other: Questionnaire<br>* Questionnaire<br>|
| Medical interns<br>Medical interns of both sexes | Other: Questionnaire<br>* Questionnaire<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the level of knowledge among pharmacists and medical interns about monkeypox treatment and nature of disease using an online Questionnaire | the level of knowledge among pharmacists and medical interns about monkeypox treatment and nature of disease using a validated questionnaire | 2 months | 
| Direct interviews with the pharmacists and medical interns to assess their knowledge and attitudes about diagnosing and dealing with the Monkeypox infected cases | Direct interviews with the pharmacists and medical interns to assess their knowledge and attitudes about diagnosing and dealing with the Monkeypox infected cases | 2 months |
Study to Assess Safety and Efficacy of DF01 in Reducing Prolonged Labor

Study Overview
=================
Brief Summary
-----------------
The study is a Proof-of-concept study to evaluate if DF01 can prevent protracted labor. Time to delivery will be measured from the time of at least 3 cm cervix dilatation and 3 contractions of minimum one minute's duration/10 minutes.

Official Title
-----------------
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Assess the Safety and Efficacy or Pre-Treatment With DF01 During Late Pregnancy in Reducing Prolonged Labor

Conditions
-----------------
Pregnancy, Labor

Intervention / Treatment
-----------------
* Drug: DF01
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy nulliparous females normal singleton pregnancy intact membranes Exclusion Criteria: breech or other abnormal presentation intercurrent illness pregnancy complications vaginal bleeding in third trimester etc

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>DF01 | Drug: DF01<br>* Once daily s.c. injections from approximately 3-7 days before expected delivery (maximum 2 weeks before) until delivery (maximum 2 weeks after expected delivery)<br>|
| Placebo Comparator: 2<br> | Drug: Placebo<br>* Once daily s.c. injections from approximately 3-7 days before expected delivery (maximum 2 weeks before) until delivery (maximum 2 weeks after expected delivery)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time from the time of at least 3 cm cervix dilatation and 3 contractions of minimum one minute's duration/10 minutes until partus in women with vaginal delivery |  | See above | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complications of labor |  | At delivery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
prolonged labor